Replimune Group, Inc.
REPLNasdaq
$10.23
↑ +7.5%Jul 17 close · end-of-day
Price
1Y↓ -19.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$949.4M
Enterprise Value
$763.8M
P/E
—
P/S
—
P/B
5.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$313.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-188.9%
ROIC
—
Debt / Equity
0.5
Net Cash
$185.6M
Return 1Y
-18.2%
Company profile
Management & directors
- Sarchi ChristopherChief Commercial Officer
- Hill Emily LuisaChief Financial Officer
- Patel SushilChief Executive Officer
- Schwendenman AndrewChief Accounting Officer
- Xynos KonstantinosChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
REPL Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.76↓ -7.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$80.0M | -$118.3M | -$177.1M | -$234.8M | -$261.6M | -$319.9M |
| Net income | -$80.9M | -$118.0M | -$174.3M | -$215.8M | -$247.3M | -$313.9M |
| Diluted EPS | -$1.75 | -$2.26 | -$2.99 | -$3.24 | -$3.07 | -$3.38 |
| Operating cash flow | -$61.4M | -$82.2M | -$128.1M | -$185.5M | -$192.3M | -$280.3M |
| Free cash flow | -$63.8M | -$84.5M | -$130.3M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$57.4M | -$58.9M | -$66.0M | -$79.3M | -$90.4M | -$84.3M | -$71.9M | -$73.3M |
| Net income | -$53.8M | -$53.1M | -$66.3M | -$74.1M | -$86.7M | -$83.1M | -$70.9M | -$73.2M |
| Diluted EPS | -$0.78 | -$0.68 | -$0.79 | -$0.82 | -$0.95 | -$0.90 | -$0.77 | -$0.76 |
| Operating cash flow | -$49.2M | -$38.6M | -$50.7M | -$53.7M | -$77.0M | -$81.2M | -$66.0M | -$56.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Coming soonHeadlines for REPL will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Sarchi Christopher· Chief Commercial Officer | Sale | 12,000 | $9.24 | $110,880.00 | filing |
| 2026-05-18 | Patel Sushil· Chief Executive Officer | Sale | 37,324 | $5.08 | $189,605.92 | filing |
| 2026-05-18 | Astley-Sparke Philip | Sale | 17,657 | $5.08 | $89,697.56 | filing |
| 2026-05-18 | Xynos Konstantinos· Chief Medical Officer | Sale | 14,023 | $5.08 | $71,236.84 | filing |
| 2026-05-18 | Sarchi Christopher· Chief Commercial Officer | Sale | 8,626 | $5.08 | $43,820.08 | filing |
| 2026-05-18 | Schwendenman Andrew· Chief Accounting Officer | Sale | 7,894 | $5.08 | $40,101.52 | filing |
| 2026-05-18 | Hill Emily Luisa· Chief Financial Officer | Sale | 7,812 | $5.08 | $39,684.96 | filing |
| 2026-04-02 | Sarchi Christopher· Chief Commercial Officer | Sale | 6,500 | $8.01 | $52,065.00 | filing |
| 2026-04-01 | Hill Emily Luisa· Chief Financial Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Sarchi Christopher· Chief Commercial Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Astley-Sparke Philip | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Xynos Konstantinos· Chief Medical Officer | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Schwendenman Andrew· Chief Accounting Officer | Award | 36,667 | $0.00 | $0.00 | filing |
| 2026-04-01 | Patel Sushil· Chief Executive Officer | Award | 251,240 | $0.00 | $0.00 | filing |
| 2026-02-18 | Astley-Sparke Philip | Gift | 25,000 | $0.00 | $0.00 | filing |
| 2025-12-19 | Patel Sushil· Chief Executive Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2025-12-19 | Xynos Konstantinos· Chief Medical Officer | Award | 60,000 | $0.00 | $0.00 | filing |
| 2025-12-19 | Sarchi Christopher· Chief Commercial Officer | Award | 35,000 | $0.00 | $0.00 | filing |
| 2025-12-19 | Schwendenman Andrew· Chief Accounting Officer | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-12-19 | Hill Emily Luisa· Chief Financial Officer | Award | 60,000 | $0.00 | $0.00 | filing |
| 2025-12-09 | Dhingra Kapil | Sale | 3,169 | $10.40 | $32,957.60 | filing |
| 2025-12-09 | Dhingra Kapil | Option exercise | 3,169 | $1.75 | $5,545.75 | filing |
| 2025-12-02 | Patel Sushil· Chief Executive Officer | Sale | 10,000 | $11.13 | $111,300.00 | filing |
| 2025-11-17 | Xynos Konstantinos· Chief Medical Officer | Sale | 7,248 | $9.10 | $65,956.80 | filing |
| 2025-11-17 | Sarchi Christopher· Chief Commercial Officer | Sale | 5,208 | $9.10 | $47,392.80 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.